Renalytix Plc (RTNXF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Renalytix Plc (RTNXF) trades at $0.08 with AI Score 43/100 (Grade C). Renalytix Plc is a healthcare company specializing in AI-enabled in vitro diagnostic solutions for kidney diseases. Market cap: $22.6M, Sector: Healthcare.
Price as of Jul 23, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for RTNXF: RTNXF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates RTNXF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
RTNXF: this read rests on a single discipline (MoonshotScore) — the other council disciplines have no scored data yet.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Renalytix Plc (RTNXF) Healthcare & Pipeline Overview
Renalytix Plc is a developer of AI-driven diagnostics for kidney disease, offering the KidneyIntelX platform that integrates biomarkers, genetics, and patient data to improve risk assessment and clinical decision-making. The company operates within the growing healthcare information services sector, focusing on early detection and personalized management of kidney conditions.
What Is the Investment Thesis for RTNXF?
Renalytix Plc presents a compelling investment thesis based on its innovative KidneyIntelX platform and strategic partnerships. The platform's ability to integrate diverse data points for personalized risk assessment in kidney disease offers a significant advantage in a market with substantial unmet needs. Key value drivers include the expansion of KidneyIntelX adoption among healthcare providers, successful execution of clinical partnerships, and potential for regulatory approvals and reimbursement coverage. However, investors may want to evaluate the company's current negative profitability, with a profit margin of -1461.6%, and the competitive landscape within the diagnostic sector. The company's high beta of 2.07 also indicates significant volatility. Successful commercialization and market penetration are crucial for Renalytix to achieve long-term sustainability and deliver value to shareholders.
Based on FMP financials and quantitative analysis
RTNXF Key Highlights
- Renalytix Plc operates in the healthcare sector, specifically within medical and healthcare information services.
- The company's primary product, KidneyIntelX, is an AI-enabled diagnostic platform for kidney disease risk assessment.
- Renalytix has established partnerships with leading healthcare institutions, including Mount Sinai Health System and Atrium Health.
- The company's market capitalization is approximately $0.02 billion as of March 16, 2026.
- Renalytix has a negative P/E ratio of -0.33 and a gross margin of 6.8%.
Who Are RTNXF's Competitors?
RTNXF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BFFTF Biofrontera AG | $0.33 | -95.24% | $19.4M | 46 |
| EMMLF OKYO Pharma Limited | $0.01 | +0.00% | $22.7M | 44 |
| GRAMF TPCO Holding Corp. | $0.16 | -15.36% | $20.1M | 42 |
| HDSLF HS GovTech Solutions Inc. | $0.39 | -0.39% | $21.1M | 46 |
| KBBTF Kubota Pharmaceutical Holdings Co., Ltd. | $0.96 | +0.00% | $24.1M | 46 |
| THKKF Think Research Corporation | $0.23 | -1.74% | $17.8M | 57 |
| AKLI Akili, Inc. | $0.43 | +0.25% | $34.1M | 67 |
| BBLN Babylon Holdings Limited | $0.55 | -13.99% | $14.1M | 56 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RTNXF's Key Strengths?
- Proprietary AI-driven diagnostic platform (KidneyIntelX).
- Strategic partnerships with leading healthcare institutions.
- Focus on a high-need area (kidney disease).
- Potential for personalized medicine applications.
What Are RTNXF's Weaknesses?
- Negative profitability and high operating expenses.
- Limited commercial traction to date.
- Reliance on partnerships for market access.
- OTC market listing may limit investor interest.
What Could Drive RTNXF Stock Higher?
- Potential regulatory approvals for KidneyIntelX from FDA or other regulatory bodies.
- Expansion of partnerships with healthcare providers and pharmaceutical companies.
- Publication of clinical studies demonstrating the efficacy of KidneyIntelX.
- Increasing adoption of KidneyIntelX among healthcare providers.
What Are the Key Risks for RTNXF?
- Financial-distress signal — its Altman Z-Score of -22.63 sits in the distress zone (elevated bankruptcy risk).
- Competition from established diagnostic companies and emerging players.
- Regulatory hurdles and changing reimbursement policies.
- Negative profitability and high operating expenses.
- Technological obsolescence.
- Economic downturn impacting healthcare spending.
What Are the Growth Opportunities for RTNXF?
- Expansion of KidneyIntelX Adoption: Renalytix has the opportunity to expand the adoption of its KidneyIntelX platform among healthcare providers and integrated delivery networks. By demonstrating the clinical and economic benefits of KidneyIntelX in improving patient outcomes and reducing healthcare costs, Renalytix can drive increased utilization and market penetration. The market for kidney disease diagnostics is estimated to be worth billions of dollars annually, providing a significant growth runway for Renalytix. Timeline: Ongoing.
- Strategic Partnerships and Collaborations: Renalytix can leverage strategic partnerships and collaborations to expand its reach and access new markets. By partnering with pharmaceutical companies, research institutions, and patient advocacy groups, Renalytix can accelerate the development and commercialization of its diagnostic solutions. These partnerships can also provide access to valuable data and insights, further enhancing the capabilities of the KidneyIntelX platform. Timeline: Ongoing.
- Regulatory Approvals and Reimbursement Coverage: Securing regulatory approvals and reimbursement coverage for KidneyIntelX is crucial for driving adoption and market access. Renalytix can pursue regulatory pathways such as FDA clearance or approval to validate the clinical utility of its platform. Obtaining favorable reimbursement coverage from payers will also be essential for ensuring that KidneyIntelX is accessible to patients and healthcare providers. Timeline: Upcoming.
- Geographic Expansion: Renalytix has the opportunity to expand its geographic footprint beyond the United States and into international markets. By targeting regions with a high prevalence of kidney disease and unmet diagnostic needs, Renalytix can tap into new revenue streams and diversify its customer base. This expansion may involve establishing partnerships with local distributors or setting up direct sales operations. Timeline: Upcoming.
- Development of New Diagnostic Solutions: Renalytix can leverage its AI and data analytics capabilities to develop new diagnostic solutions for other kidney-related conditions and diseases. By expanding its product portfolio, Renalytix can address a broader range of clinical needs and increase its market share. This may involve developing new biomarkers, algorithms, or diagnostic platforms. Timeline: Ongoing.
What Opportunities Does RTNXF Have?
- Expansion of KidneyIntelX adoption among healthcare providers.
- Securing regulatory approvals and reimbursement coverage.
- Geographic expansion into international markets.
- Development of new diagnostic solutions for kidney-related conditions.
What Threats Does RTNXF Face?
- Competition from established diagnostic companies.
- Regulatory hurdles and changing reimbursement policies.
- Technological obsolescence.
- Economic downturn impacting healthcare spending.
What Are RTNXF's Competitive Advantages?
- Proprietary AI-enabled KidneyIntelX platform.
- Strategic partnerships with leading healthcare institutions.
- Extensive data and biomarker library for algorithm training.
- First-mover advantage in the AI-driven kidney diagnostics market.
What Does RTNXF Do?
Renalytix Plc, formerly known as Renalytix AI plc, was incorporated in 2018 and is headquartered in New York City. The company is focused on developing artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. Its primary product is KidneyIntelX, a diagnostic platform that utilizes an AI-enabled algorithm to combine data inputs such as blood-based biomarkers, inherited genetics, and patient data from electronic health records. This platform generates a patient-specific risk score, aiding in kidney disease diagnosis, prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix has established licensing agreements with institutions like Mount Sinai Health System, Joslin Diabetes Center, Inc., and Kantaro Biosciences LLC to develop and commercialize products related to AI-driven kidney disease diagnosis and antibody detection for SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. Renalytix aims to transform kidney disease management by providing clinicians with actionable insights to improve patient outcomes and reduce healthcare costs.
What Products and Services Does RTNXF Offer?
- Develops AI-enabled in vitro diagnostic solutions for kidney diseases.
- Offers KidneyIntelX, a diagnostic platform using an AI algorithm.
- Combines blood-based biomarkers, genetics, and patient data for risk assessment.
- Provides insights for kidney disease diagnosis and prognosis.
- Supports clinical care and patient stratification for clinical trials.
- Aids in drug target discovery for kidney disease treatments.
How Does RTNXF Make Money?
- Generates revenue through the sale of KidneyIntelX diagnostic tests.
- Partners with healthcare providers and institutions for test utilization.
- Licenses its technology and data to pharmaceutical companies and research organizations.
- Forms strategic alliances to expand market reach and product offerings.
What Industry Does RTNXF Operate In?
Renalytix Plc operates within the healthcare information services industry, which is experiencing growth driven by the increasing adoption of AI and data analytics in healthcare. The market for kidney disease diagnostics is substantial, with a growing prevalence of chronic kidney disease (CKD) globally. The competitive landscape includes established diagnostic companies and emerging players focused on AI-driven solutions. Renalytix aims to differentiate itself through its integrated KidneyIntelX platform and strategic partnerships with healthcare providers. The industry is subject to regulatory oversight and reimbursement policies, which can impact market access and adoption.
Who Are RTNXF's Key Customers?
- Healthcare providers (nephrologists, primary care physicians).
- Hospitals and integrated delivery networks.
- Pharmaceutical companies conducting clinical trials.
- Research institutions studying kidney disease.
How Renalytix Plc Is Valued
Renalytix Plc carries a market capitalization of $22.6M, placing it in the micro-cap category. Relative to its peer group, RTNXF's quantitative score of 43/100 is roughly in line with the peer average of 45/100.
F-Score 4/9Financial Health
Renalytix Plc's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -22.63 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Renalytix Plc revenue of about $61.8M for fiscal 2026, with EPS near $-0.22.
RTNXF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Proprietary AI-driven diagnostic platform (KidneyIntelX).
- Strategic partnerships with leading healthcare institutions.
- Focus on a high-need area (kidney disease).
- Potential for personalized medicine applications.
Bear Case
- Negative profitability and high operating expenses.
- Limited commercial traction to date.
- Reliance on partnerships for market access.
- OTC market listing may limit investor interest.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
RTNXF Latest News
No recent news available for RTNXF.
RTNXF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for RTNXF.
Price Targets
Wall Street price target analysis for RTNXF.
RTNXF MoonshotScore
What does this score mean?
The MoonshotScore rates RTNXF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: James R. McCullough
CEO
James R. McCullough serves as the CEO of Renalytix Plc, leading the company's efforts in developing and commercializing AI-enabled diagnostics for kidney disease. His background includes experience in the healthcare and technology sectors, with a focus on commercial strategy and market development. He has held leadership positions in various companies, driving growth and innovation in the diagnostic and biotechnology fields. McCullough's expertise spans across areas such as product development, sales, and marketing, contributing to his ability to steer Renalytix towards its strategic goals.
Track Record: Under James R. McCullough's leadership, Renalytix Plc has focused on expanding the adoption of its KidneyIntelX platform and establishing strategic partnerships with healthcare institutions. Key milestones include securing agreements with leading healthcare providers and advancing regulatory efforts to validate the clinical utility of KidneyIntelX. The company has also focused on expanding its data and biomarker library to enhance the capabilities of its AI-driven diagnostic solutions. However, the company is still loss-making.
RTNXF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Renalytix Plc may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting, regulatory oversight, and investor protection compared to those listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the potential for limited information, liquidity, and regulatory scrutiny.
- OTC Tier: OTC Other
- Limited financial disclosure and regulatory oversight.
- Lower trading volumes and liquidity.
- Potential for price volatility and manipulation.
- Higher risk of fraud or mismanagement.
- Limited investor protection compared to major exchanges.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and legal risks.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any news or press releases about the company.
- Established partnerships with reputable healthcare institutions.
- Proprietary AI-driven diagnostic platform (KidneyIntelX).
- Focus on a high-need area (kidney disease).
- Experienced management team with healthcare and technology expertise.
RTNXF Healthcare Stock FAQ
What does the AI Score mean for RTNXF?
RTNXF holds an AI Score of 43/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Renalytix Plc is a healthcare company specializing in AI-enabled in vitro diagnostic solutions for kidney diseases. Their KidneyIntelX platform aims to improve diagnosis, prognosis, and clinical …
What does Renalytix Plc do?
Renalytix Plc is a healthcare company specializing in the development and commercialization of AI-enabled in vitro diagnostic solutions for kidney diseases. The company's primary product, KidneyIntelX, is a diagnostic platform that utilizes an AI algorithm to combine data inputs such as blood-based biomarkers, inherited genetics, and patient data from electronic health records.
What are the main risks for RTNXF?
Renalytix Plc faces several risks, including competition from established diagnostic companies and emerging players in the AI-driven healthcare space. Regulatory hurdles and changing reimbursement policies could impact the adoption and market access of KidneyIntelX. The company's negative profitability and high operating expenses pose financial challenges. Technological obsolescence and the potential for economic downturns impacting healthcare spending are also significant risks.
What are the key factors to evaluate for RTNXF?
Renalytix Plc (RTNXF) holds an AI score of 43/100 (low). Not financial advice.
How frequently does RTNXF data refresh on this page?
RTNXF's price was last updated on Jul 23, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven RTNXF's recent stock price performance?
Renalytix Plc (RTNXF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary AI-driven diagnostic platform (KidneyIntelX). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RTNXF overvalued or undervalued right now?
Renalytix Plc (RTNXF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research RTNXF before investing?
Before investing in Renalytix Plc (RTNXF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding RTNXF to a portfolio?
Key strength of Renalytix Plc (RTNXF): Proprietary AI-driven diagnostic platform (KidneyIntelX). Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- OTC market investments carry additional risks.
- AI analysis is pending and may provide further insights.